Trending Topic

Musculoskeletal AI image
16 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Samantha Cooray, Alexander Deng, Tim Dong

There is much excitement about the deployment of artificial intelligence (AI) in healthcare, and the musculoskeletal field is no exception. In this article, we introduce some of the latest developments relating to osteoarthritis (OA), osteoporosis, rheumatoid arthritis (RA) (as an example of inflammatory arthritis), connective tissue disease (CTD), Ehlers–Danlos syndrome (EDS) and musculoskeletal surgical interventions. […]

Hyun C Chung, ASCO GI 2021: Lenvatinib plus Pembrolizumab in Patients with Advanced Solid Tumours

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Feb 1st 2021

We were delighted to talk to Hyun C Chung (Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea) about the combination of lenvatinib plus pembrolizumab in the treatment of patients with advanced solid tumours (Clinical Trial Identifier: NCT03797326).

The abstract ‘LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors: Results from the gastric cancer cohort.’ (ABSTRACT NUMBER: 230) was presented at the virtual ASCO Gastrointestinal Cancers Symposium 2021, 15-17 January, 2021.

Questions

  1. What is the rationale for the use of lenvatinib plus pembrolizumab in patients with advanced solid tumours? (0:05)
  2. Which patients are most likely to respond to this combination? (1:06)

Disclosures: Hyun C Chung discloses Grant/Research Support from Lilly, GSK, MSD, Merck-Serono, BMS/Ono, Taiho, Amgen, Beigene, Incyte and Zymework; Honoraria from Merck-Serono and Lilly; Consultation for Taiho, Celltrion, MSD, Lilly, BMS, Merck-Serono, Gloria, Beigene, Amgen and Zymework.

Support: Interview and filming supported by Touch Medical Media.

Filmed as a highlight of ASCO GI 2021 (Virtual).

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup